{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
BLA125737
(2021)
Source URL:
First approved in 2021
Source:
BLA125737
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA125737
(2021)
Source URL:
First approved in 2021
Source:
BLA125737
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA125737
(2021)
Source URL:
First approved in 2021
Source:
BLA125737
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Sotrovimab by GlaxoSmithKline LLC
(2021)
Source URL:
First approved in 2021
Source:
Sotrovimab by GlaxoSmithKline LLC
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA125659
(2021)
Source URL:
First approved in 2021
Source:
BLA125659
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02913170: Phase 4 Interventional Completed Hypercholesterolemia
(2015)
Source URL:
First approved in 2021
Source:
Vigen Dr. Nattokinase by Vigen medical
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M020
(2021)
Source URL:
First approved in 2021
Source:
M020
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M020
(2021)
Source URL:
First approved in 2021
Source:
M020
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
PROTEIN
